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Accepted 21 December 2012The treatment paradigms for myeloma have dramatically
changed in the past decadewith availability of more effective
drugs, and patients are living substantially longer [1]. These
changes, along with a better understanding of the genetic
underpinnings of the disease, have changed our approach to
management of patients with myeloma. The study by Kroger
and colleagues [2] highlights two of the most debated
questions in myeloma today: What should be the goal of
myeloma therapy and how do we approach patients with
high-risk multiple myeloma?
The increasing depth of response seen with the new drug
combinations and increasing use of post-transplant consol-
idation and maintenance approaches have seen nearly 100%
of patients getting a partial response and nearly half of
patients obtaining a complete response (CR), as deﬁned by
the International MyelomaWorking Group (IMWG) response
criteria [3,4]. These high response rates have pushed the
boundaries of the current response criteria, highlighting the
need for better markers of residual tumor given that most
patients in CR eventually relapse. In response to this, the
IMWG criteria was revised to add a category of stringent CR
that required normalization of serum free light chains as well
as lack of clonally restricted plasma cells in the marrow [4].
However, it is clear that more sensitive and speciﬁc markers
of minimal residual disease are needed.
Two methodologies have been studied extensively,
although no consensus exists as to the exact methodologies
and deﬁnitions for minimal residual disease negativity [5,6].
Polymerase chain reactionebased methods clearly have
a high sensitivity and speciﬁcity but suffer from the inability
to create patient-speciﬁc primers in nearly half of patients.
Flow cytometryebased methods have gained signiﬁcant
foothold in the recent years due to several technological
advances such as six- and eight-color ﬂow cytometers, the
ability to automate the process and study over million cells
from individual samples, and the development of new ﬂuo-
rochromes and better antibodies [7].
There have been different algorithmic approaches to
deﬁning presence of minimal residual disease in a ﬂow
cytometry sample. Some centers used baseline aberrantFinancial disclosure: See Acknowledgments on page 336.
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or CD20 to “ﬁngerprint” myeloma cells at baseline followed
by serial examination for phenotypically similar cells to
detect residual myeloma cells [8]. Others have depended on
the typical antigenic proﬁle of myeloma cell followed by
clonality determination using kappa and lambda expression
[9]. An additional method used by Kroger et al. is to examine
the plasma cell chimerism; however, this methods requires
additional validation.
Consensus has eluded this area, but with increasing
utilization of this technique in recent years, wewill likely see
uniform standards being developed in this area. However,
increasing sensitivity of the tests are likely to elevate the
debate in the ﬁeld as to how deep a response the goal of
therapy should be. Deeper responses have always trans-
formed into longer disease control, and most studies also
suggest that attainment of deeper states of response leads to
better overall survival [10]. However, the studies so far have
not been able to deﬁnitively answer the question as to
whether additional therapy with the goal of inducing a CR in
a given patient translates to better outcome, thus proving
that the impact of CR is not just a reﬂection of the disease
biology. Clinical trials examining response-adapted treat-
ment strategies are needed to answer this question
deﬁnitively.
The second area of considerable importance addressed by
Kroger et al. is the outcome of patients with high-risk
myeloma. Nearly 25% of patients with myeloma die in the
ﬁrst 3 years of diagnosis despite improvements in median
survival for all patients exceeding 8 years currently. Even
intense approaches such as total therapy protocols have
failed to make much of a dent in this high-risk population
[11]. Although randomized trials of allogeneic trans-
plantation have not shown overall survival beneﬁt in
myeloma, high-risk myeloma is an area where allogeneic
approaches may have a distinct role [12,13]. Unfortunately,
randomized trials of allogeneic transplantation in myeloma
have not strictly deﬁned the high-risk population as we
currently do with ﬂuorescence in situ hybridizationebased
abnormalities such as 17p deletion and the t(4;14), t(14;16)
and t(14;20) transplantations.
Kroger et al. were unable to demonstrate any difference in
progression-free survival for the high-risk group, which is an
encouraging ﬁnding. Clearly, this is a rather small, retro-
spective study that included patients during a time where
treatments for the disease have dramatically changed.
However, these results should spur interest in developing
randomized trials examining the utility of this modality in
these patients.
Finally, there has been increasing skepticism about the
ability of reduced-intensity regimens to induce meaningful
responses in myeloma. Kroger et al. demonstrated the ability
P. Armand / Biol Blood Marrow Transplant 19 (2013) 335e337336to induce molecular remissions in a proportion of patients,
which in turn has translated to improved progression-free
and overall survival. Their results underscore the impor-
tance of designing prospective trials to better deﬁne the role
of allogeneic transplant in myeloma, speciﬁcally the patient
population that might beneﬁt and the conditioning approach
that is most appropriate.ACKNOWLEDGMENTS
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a large number of publications have reported a strong asso-
ciation between elevated serum ferritin before allogeneic
hematopoietic stem cell transplantation (HSCT) and
decreased post-HSCT overall survival (OS). Although this
association is now beyond doubt, many areas of uncertainty
remain.
In this context, the study of Dr. Meyer and colleagues [2]
in this issue of Biology of Blood and Marrow Transplantation
adds both light and darkness. They report the dynamic
behavior of serum iron parameters, most notably ferritin,
among 290 patients who underwent myeloablative HSCT at
their center. As previously described, ferritin levels increasedin the few months after transplantation and then decreased
to below pre-HSCT levels in long-term survivors. They also
could conﬁrm that pre-HSCT ferritin is associated with
increased nonrelapse mortality (NRM) and decreased OS.
However, the most important ﬁnding of this study is that an
elevated ferritin was associated with increased mortality
even in 6-, 12-, and 24-month landmark analyses. This effect
appeared to depend on both an increased risk of relapse and
an increased risk of NRM in patients with elevated ferritin.
Thisﬁnding can be interpreted in at least three differentways.
First, it is possible that iron overload is indeed detri-
mental after HSCT, as previously assumed based on ferritin
studies and for the reasons previously adduced: increased
risk of infection, especially fungal, and liver toxicity. The
present study would suggest that this effect extends to long-
term survivors of HSCT. However, this seems the least likely
explanation. Indeed, long-termmortality after HSCT depends
primarily on disease relapse and complications of chronic
graft-versus-host disease (GVHD), not liver toxicity (which is
a very rare cause of death after the early post-HSCT period)
or fungal infection (outside of the context of chronic
GVHD and immunosuppression). There has been little
evidence to date that hyperferritinemia is associated with
the subsequent development of chronic GVHD. In Dr. Meyer’s
study, the adverse effect of hyperferritinemia on long-term
survivors was primarily due to relapse, not NRM, which is
